NEW YORK, July 1, 2014 /PRNewswire/ -- Manhattan Scientifics, Inc. (OTCQB: MHTX) MHTX is an emerging technology incubator/venture firm focused on technology transfer and commercialization of disruptive technologies in the nanomedicine space. The company is presently developing commercial medical prosthetics applications for its ultrafine grain metals and plans to commercialize the cancer research work and nanomedical applications developed by Senior Scientific LLC, a unit of the Company.
The Company has some promising partner relationships most notably with Los Alamos National Laboratory in New Mexico and is developing a stable of potential partners for future growth. The Company has also recently announced that it has delivered its break-through, cancer measurement instrument to The University of Texas M.D. Anderson Cancer Center in Houston, TX. On January 27th 2014, the company executed an agreement to collaborate with M.D. Anderson to advance, demonstrate and validate a breakthrough technology developed by Edward R. Flynn, PhD. Dr. Flynn is the founder and chief scientist of the company's subsidiary, Senior Scientific LLC.
An analyst report which details key attributes of the products, an overview of the company, Competitive analysis, recent developments, risk factors and analyst recommendation can be viewed in its entirety by using the link below. There is no cost obligation required to view this report:
Copy and paste to browser may be required.
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is written and authored by Michael Anderegg, Chartered Financial Analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.
A full disclaimer can be found by viewing the full analyst report.
If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at email@example.com. For any urgent concerns or inquiries please contact us at firstname.lastname@example.org.
BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.
SOURCE BrokerBank Securities, Inc.